اخبار و اعلانات

 آمار

تعداد نشریات287
تعداد نشریات سازمان85
تعداد شماره‌ها3,159
تعداد مقالات35,108
تعداد مشاهده مقاله50,529,830
تعداد دریافت فایل اصل مقاله90,478,319
Al-Mohammed Amin, Y. M. I, Faisal Hatem Al-Mugdadi, S, Mahmood Mohammed, M. (1402). Levels of APE1 Repair Gene and CLEC4M in Lung Cancer Patients Receiving Cisplatin Chemotherapy. سامانه مدیریت نشریات علمی, 78(3), 963-972. doi: 10.22092/ari.2022.360397.2578
Y. M. I Al-Mohammed Amin; S Faisal Hatem Al-Mugdadi; M Mahmood Mohammed. "Levels of APE1 Repair Gene and CLEC4M in Lung Cancer Patients Receiving Cisplatin Chemotherapy". سامانه مدیریت نشریات علمی, 78, 3, 1402, 963-972. doi: 10.22092/ari.2022.360397.2578
Al-Mohammed Amin, Y. M. I, Faisal Hatem Al-Mugdadi, S, Mahmood Mohammed, M. (1402). 'Levels of APE1 Repair Gene and CLEC4M in Lung Cancer Patients Receiving Cisplatin Chemotherapy', سامانه مدیریت نشریات علمی, 78(3), pp. 963-972. doi: 10.22092/ari.2022.360397.2578
Al-Mohammed Amin, Y. M. I, Faisal Hatem Al-Mugdadi, S, Mahmood Mohammed, M. Levels of APE1 Repair Gene and CLEC4M in Lung Cancer Patients Receiving Cisplatin Chemotherapy. سامانه مدیریت نشریات علمی, 1402; 78(3): 963-972. doi: 10.22092/ari.2022.360397.2578

Levels of APE1 Repair Gene and CLEC4M in Lung Cancer Patients Receiving Cisplatin Chemotherapy

Archives of Razi Institute
مقاله 23، دوره 78، شماره 3، مرداد و شهریور 2023، صفحه 963-972    اصل مقاله (454.16 K)
نوع مقاله: Original Articles
شناسه دیجیتال (DOI): 10.22092/ari.2022.360397.2578
نویسندگان
Y. M. I Al-Mohammed Amin* 1؛ S Faisal Hatem Al-Mugdadi1؛ M Mahmood Mohammed2
1Department of Clinical Laboratory Sciences, College of Pharmacy, Mustansiriyah University, Baghdad, Iraq
2Department of Clinical Pharmacy , College of Pharmacy, Mustansiriyah University, Baghdad, Iraq
چکیده
This study aimed to detect the levels of apurinic/apyrimidinic endonuclease 1 (APE1) gene expression and C-type lectin domain family 4 member M (CLEC4M) and their association with cisplatin chemotherapy in lung cancer patients. Overall, 105 individuals who attended the Al-Amal National Hospital for Cancer Management, Baghdad, Iraq, were enrolled in the study and divided into three equal groups. The groups included the patients newly diagnosed with lung cancer, cancer patients who received cisplatin, and the healthy control group. All study groups were subjected to the sampling of the venous blood for molecular analysis by real-time polymerase chain reaction (RT-PCR) to detect the APE1 gene and enzyme-linked immunosorbent assay (ELISA) for serological testing to measure the concentration of CLEC4M protein. Significantly, the values of both cancer groups were higher than those reported in the control group. The relative index revealed a significant difference in the mean fold change level of APE1 in the newly diagnosed group (3 fold) and cisplatin therapy patients group (2 fold), compared to the control group (P=0.005). No significant differences were detected between the two cancer groups in terms of fold change mean of expression, demographic characteristics, and cancer histological type. Regarding human CLEC4M protein level, cases receiving cisplatin (139.2±25.9) and newly diagnosed patients (331.0±38.1) had a highly significant difference with the control group (100.3±47.5, P<0.001). There was no significant difference between the concentration level of CLEC4M and all parameters in demographic characteristics and cancer histological type. This was the first study to demonstrate that higher expression levels of new APE1, CLEC4M, and glutathione, especially after chemotherapy, are beneficial as diagnostic and prognostic markers for resistance to platinum chemotherapy in Iraqi lung cancer patients.
کلیدواژه‌ها
Apurinic/Apyrimidinic Endonuclease 1؛ Cisplatin؛ C-Type Lectin Domain Family 4 Member M؛ Platinum chemotherapy
سایر فایل های مرتبط با مقاله
مراجع
  1. Zaorsky NG, Churilla TM, Egleston BL, Fisher SG, Ridge JA, Horwitz EM, et al. Causes of death among cancer patients. Ann Oncol. 2017;28(2):400-7.
  2. Barta JA, Powell CA, Wisnivesky JP. Global Epidemiology of Lung Cancer. Ann Glob Health. 2019;85(1).
  3. Tsao AS, Scagliotti GV, Bunn PA, Jr., Carbone DP, Warren GW, Bai C, et al. Scientific Advances in Lung Cancer 2015. J Thorac Oncol. 2016;11(5):613-38.
  4. Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014;740:364-78.
  5. Zivanovic O, Abramian A, Kullmann M, Fuhrmann C, Coch C, Hoeller T, et al. HIPEC ROC I: a phase I study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum-based chemotherapy in patients with platinum-sensitive recurrent epithelial ovarian cancer. Int J Cancer. 2015;136(3):699-708.
  6. Rocha CRR, Silva MM, Quinet A, Cabral-Neto JB, Menck CFM. DNA repair pathways and cisplatin resistance: an intimate relationship. Clinics (Sao Paulo). 2018;73(1):478.
  7. Gridelli C, Aapro M, Ardizzoni A, Balducci L, De Marinis F, Kelly K, et al. Treatment of advanced non-small-cell lung cancer in the elderly: results of an international expert panel. J Clin Oncol. 2005;23(13):3125-37.
  8. Sengupta S, Mitra S, Bhakat KK. Dual regulatory roles of human AP-endonuclease (APE1/Ref-1) in CDKN1A/p21 expression. PLoS One. 2013;8(7):e68467.
  9. Thakur S, Dhiman M, Tell G, Mantha AK. A review on protein-protein interaction network of APE1/Ref-1 and its associated biological functions. Cell Biochem Funct. 2015;33(3):101-12.
  10. Ayyildiz D, Antoniali G, D'Ambrosio C, Mangiapane G, Dalla E, Scaloni A, et al. Architecture of The Human Ape1 Interactome Defines Novel Cancers Signatures. Sci Rep. 2020;10(1):28.
  11. Manoel-Caetano FS, Rossi AFT, Calvet de Morais G, Severino FE, Silva AE. Upregulation of the APE1 and H2AX genes and miRNAs involved in DNA damage response and repair in gastric cancer. Genes Dis. 2019;6(2):176-84.
  12. Tan LM, Li X, Qiu CF, Zhu T, Hu CP, Yin JY, et al. CLEC4M is associated with poor prognosis and promotes cisplatin resistance in NSCLC patients. J Cancer. 2019;10(25):6374-83.
  13. Zhang F, Ren S, Zuo Y. DC-SIGN, DC-SIGNR and LSECtin: C-type lectins for infection. Int Rev Immunol. 2014;33(1):54-66.
  14. Fu D, Zhang B, Yang L, Huang S, Xin W. Development of an Immune-Related Risk Signature for Predicting Prognosis in Lung Squamous Cell Carcinoma. Front Genet. 2020;11:978.
  15. Li Z, Qing Y, Guan W, Li M, Peng Y, Zhang S, et al. Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-paclitaxel chemotherapy. Cancer Chemother Pharmacol. 2014;74(4):777-86.
  16. Long K, Gu L, Li L, Zhang Z, Li E, Zhang Y, et al. Small-molecule inhibition of APE1 induces apoptosis, pyroptosis, and necroptosis in non-small cell lung cancer. Cell Death Dis. 2021;12(6):503.
  17. Wang X, Yue H, Li S, Guo J, Guan Z, Zhu Z, et al. Genetic Polymorphisms in DNA Repair Gene APE1/Ref-1 and the Risk of Neural Tube Defects in a High-Risk Area of China. Reprod Sci. 2021;28(9):2592-601.
  18. Burgess JT, Rose M, Boucher D, Plowman J, Molloy C, Fisher M, et al. The Therapeutic Potential of DNA Damage Repair Pathways and Genomic Stability in Lung Cancer. Front Oncol. 2020;10:1256.
  19. Xiong Y, Huang BY, Yin JY. Pharmacogenomics of platinum-based chemotherapy in non-small cell lung cancer: focusing on DNA repair systems. Med Oncol. 2017;34(4):48.
  20. Collins AR, Harrington V, Drew J, Melvin R. Nutritional modulation of DNA repair in a human intervention study. Carcinogenesis. 2003;24(3):511-5.
  21. Poletto M, Di Loreto C, Marasco D, Poletto E, Puglisi F, Damante G, et al. Acetylation on critical lysine residues of Apurinic/apyrimidinic endonuclease 1 (APE1) in triple negative breast cancers. Biochem Biophys Res Commun. 2012;424(1):34-9.
  22. Mio C, Gerratana L, Bolis M, Caponnetto F, Zanello A, Barbina M, et al. BET proteins regulate homologous recombination-mediated DNA repair: BRCAness and implications for cancer therapy. Int J Cancer. 2019;144(4):755-66.
  23. Luo L, Chen L, Ke K, Zhao B, Wang L, Zhang C, et al. High expression levels of CLEC4M indicate poor prognosis in patients with hepatocellular carcinoma. Oncol Lett. 2020;19(3):1711-20.
  1. Tell G, Demple B. Base excision DNA repair and cancer. Oncotarget. 2015;6(2):584-5.
  2. Pascut D, Sukowati CHC, Antoniali G, Mangiapane G, Burra S, Mascaretti LG, et al. Serum AP-endonuclease 1 (sAPE1) as novel biomarker for hepatocellular carcinoma. Oncotarget. 2019;10(3):383-94.
  3. Malfatti MC, Gerratana L, Dalla E, Isola M, Damante G, Di Loreto C, et al. APE1 and NPM1 protect cancer cells from platinum compounds cytotoxicity and their expression pattern has a prognostic value in TNBC. J Exp Clin Cancer Res. 2019;38(1):309.
  4. Zhang S, He L, Dai N, Guan W, Shan J, Yang X, et al. Serum APE1 as a predictive marker for platinum-based chemotherapy of non-small cell lung cancer patients. Oncotarget. 2016;7(47):77482-94.
  5. Kelley MR, Jiang Y, Guo C, Reed A, Meng H, Vasko MR. Role of the DNA base excision repair protein, APE1 in cisplatin, oxaliplatin, or carboplatin induced sensory neuropathy. PLoS One. 2014;9(9):e106485.
  6. Zhang H, Ba S, Yang Z, Wang T, Lee JY, Li T, et al. Graphene Quantum Dot-Based Nanocomposites for Diagnosing Cancer Biomarker APE1 in Living Cells. ACS Appl Mater Interfaces. 2020;12(12):13634-43.
  7. Chen SH, Chang JY. New Insights into Mechanisms of Cisplatin Resistance: From Tumor Cell to Microenvironment. Int J Mol Sci. 2019;20(17).
  1. Yang X, Peng Y, Jiang X, Lu X, Duan W, Zhang S, et al. The regulatory role of APE1 in epithelial-to-mesenchymal transition and in determining EGFR-TKI responsiveness in non-small-cell lung cancer. Cancer Med. 2018;7(9):4406-19.
  2. Rouillon C, White MF. The evolution and mechanisms of nucleotide excision repair proteins. Res Microbiol. 2011;162(1):19-26.
  3. Acklin S, Xia F. The Role of Nucleotide Excision Repair in Cisplatin-Induced Peripheral Neuropathy: Mechanism, Prevention, and Treatment. Int J Mol Sci. 2021;22(4).
  4. Budisan L, Gulei D, Jurj A, Braicu C, Zanoaga O, Cojocneanu R, et al. Inhibitory Effect of CAPE and Kaempferol in Colon Cancer Cell Lines-Possible Implications in New Therapeutic Strategies. Int J Mol Sci. 2019;20(5).
  5. Yu Q, Gao K. CLEC4M overexpression inhibits progression and is associated with a favorable prognosis in hepatocellular carcinoma. Mol Med Rep. 2020;22(3):2245-52.
  6. Ballatori N, Krance SM, Notenboom S, Shi S, Tieu K, Hammond CL. Glutathione dysregulation and the etiology and progression of human diseases. Biol Chem. 2009;390(3):191-214.
آمار
تعداد مشاهده مقاله: 3,014
تعداد دریافت فایل اصل مقاله: 7,559


counter
سامانه مدیریت نشریات علمی. طراحی و پیاده سازی از سیناوب